fda pediatric advisory committee june 30, 2005 marsha d. rappley, md

34
FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Upload: ferdinand-riley

Post on 27-Dec-2015

217 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

FDA Pediatric Advisory Committee

June 30, 2005

Marsha D. Rappley, MD

Page 2: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Managing Children and Adolescents with ADHD

in Primary Care

• Source of referrals

• Issues in diagnosis

• Treatment options**Medications in treatment of ADHD**

• Choice of medication• Establishing an effective dose• Monitoring for effectiveness and side effects

Page 3: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Source of referrals

• Most children and adolescents with ADHD are managed in primary care– ADHD is one of the most common reasons for an

office visit for school aged children– Stimulant medications are among the 10 most

frequently prescribed medications for children

• Referrals– Self referrals from the primary care practice– Referrals from schools– Referrals to pediatrics from family practice

Page 4: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Diagnostic issues

• Guidelines– American Academy of Pediatrics

• Adopted by American Academy of Family Physicians

– American Academy of Child and Adolescent Psychiatry

– European groups as well

Page 5: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Common to these guidelines

• Comprehensive history

• Information from important domains of the child’s life– More than one source– Typically parents, school and child or teen

• Use of standardized checklists• Allows comparisons of behavior to children of

same age

• Asses for co-existing conditions

Page 6: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Common to these guidelines

• ADHD as chronic health condition• Establishment of treatment goals• Medication with stimulants to manage

symptoms• Behavior therapy for parent-child conflict,

oppositional behavior; psychological therapy for co-existing conditions

Taken together, these guidelines establish a standard of care

Page 7: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Considering treatmentfor ADHD

• Inattention: Medication– Methylphenidate– Dextroamphetamine products (including mixed

salts)– Atomoxetine– Bupropion

• Hyperactivity and Impulsivity: Medication

• Oppositional behavior: Med + Counseling

• Parent child conflict: Med + Counseling

Page 8: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Considering medications

• Stimulants first line– Most effective: 68-80%– 3-4% experience side effects causing

discontinuation of medications– Provide targeted coverage– Available as generic– Products with duration

• 2 -4 hr, 4 – 8 hr, 8 – 12 hr

Page 9: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Considering medications

• Atomoxetine second line– Effective 50 – 60%– Similar side effects to stimulants– Provides 24 hour coverage– 1-3 weeks to reach effect

• Bupropion– Fewer studies, more serious side effects– Role of antidepressant effect– 24 hour coverage with twice daily dosing– 3-4 weeks to reach effect

Page 10: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Choosing a medication

• Stimulant usually chosen for most children and teens– MPH and DEX have similar profiles– DEX slightly more side effects, which are mild– Mixed salt preparation (Adderall®)

• Recent withdrawal of long acting product in Canada

• Warning of use in children with cardiac conditions

• Parent may have preference

Page 11: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Setting target outcomes

• Measurable desired outcomes are preferred– Inattention

• Work completion, time on homework, spelling tests, timed math tests, fluidity of thinking and writing (copying from the board, note taking)

– Hyperactivity and impulsivity• Calls from school, episodes of detention,

participation in activities without disruption (cub scouts, sports)

Page 12: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Setting target outcomes

• Quality of relationships– Peers: teasing, friendship, time in play– Teachers: decreasing negative, increasing

positive interactions, engagement in learning activities

– Parents: decreasing negative, increasing positive interactions, time for affection and support

– Siblings: decreasing negative, increasing positive interactions, decreasing reactivity,

Page 13: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Setting target outcomes

• Severe ADHD: safety concerns may be priority

• Treatment goals that make sense to the child

• Treatment goals that make sense to the parents

Page 14: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Choosing an initial medication

• First decision: longer or shorter acting?– Should relate to target goals– Long acting obviates need for mid school day

dose• Especially important with older school aged and

teens

– Short acting allows targeting times of day• May be important for younger child in half day of

school– If target goal is school related only and parents are

tolerant of behaviors at home

Page 15: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Choosing an initial product

• Largely dictated by insurance coverage– Many cover at least one long acting

preparation

• Cost difference between generic shorter duration and name brand long acting may be > $100/mo, depending on dose.

Page 16: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Choosing an initial dose

• Aim for lowest dose likely to be effective– In past, starting routinely at very low dose, but

safety at effective doses established with large randomized controlled studies

• Younger child, slight child, primarily inattentive: lower dose to start

• Older, or symptoms more severe: moderate doses to start

Page 17: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Doses

• DEX higher potency than MPH

• Dosing Intervals– Short acting: 2 to 4 doses per day– Longer acting

• 1 dose per day• Or 7 am dose long acting and 5pm dose short

acting of same medication– Ex: Concerta® or Ritalin LA® in am and generic MPH in

late afternoon

Page 18: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Doses

• Lower doses, per dose– Short acting

• 5 – 10 mg. MPH, 5 mg. DEX

– Longer acting• 10 – 27 mg. MPH; 5 – 10 mg DEX

• Moderate doses, per dose– Short acting

• 20 mg. MPH, 10 – 20 mg. DEX

– Longer acting• 39 – 54 mg MPH; 30 – 40 mg. DEX

Page 19: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Doses• Higher doses

– Short acting• > 20 mg per dose MPH or DEX• Or > 60 mg per day MPH or DEX

– Long acting• > 72 mg per dose MPH, > 40 mg DEX• > 54 mg in younger child MPH, > 30 mg DEX

• Higher doses used in more severe cases• Guidelines: titrate to benefit without side

effects

Page 20: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Monitoring medication

• Optimal frequency of follow up is not well studied

• Many recommend follow up visits every 3 to 4 months once dose is established

• Allows monitoring effectiveness• Allows monitoring side effects

Page 21: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Monitoring medication

• If intervals longer than every 4 months– Potential for med to be continued when not

effective– Potential for med to be prematurely

discontinued or other meds selected, which might have more side effects

– Potential for mild side effects to be unnecessarily tolerated for most of school year

Page 22: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Monitoring medication

• Very young children and those with co-existing conditions need visits every 3 months when stable– More difficult diagnostic challenge– Greater possibility of developmental progress

in symptoms for very young child– More side effects in younger children– Distinct possibility of under treated co-existing

condition– Possibility of co-existing condition primary,

rather than ADHD

Page 23: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Monitoring for side effects

• At all visits– Blood pressure, pulse, height, weight

• Appetite, headache, abdominal pain, sleep

• Tics, mood changes, irritability

• “Rebound” phenomena

• Most side effects are responsive to changes in dose or timing

Page 24: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Appetite suppression

• Expected in perhaps 80% patients

• For most children and families, awareness of need to provide good caloric intake prevents or solves problem

• Problem is more pronounced in younger children

Page 25: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Appetite suppression

• Some children must find their own food and fail to gain weight on stimulants

• Some families are rigid about food and mealtime and children fail to gain on stimulants

• Some children fail to gain weight and this is not apparent until height is affected– Illustrates importance of follow up visits

Page 26: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Headache and “stomach ache”

• These may respond to taking medication with food

• Many kids, all ages, go to school without breakfast, are not hungry at lunch due to medication, and experience headaches, abdominal pain and mood changes

• May occur in first few days of medication, but usually not severe enough to interrupt activities

Page 27: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Delayed sleep onset

• Important to establish baseline sleep patterns

• Recent research indicates difficulty with sleep onset may be associated with disorder rather than medication

• Other research indicates medication

• Usually responsive to timing of last dose

Page 28: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Onset of tics, tic disorder

• Important to note baseline behaviors, mannerisms, family history of tics

• Tics may not be recognized as such by patient, family or teacher

• Not contraindication to treatment with stimulants

Page 29: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Mood changes, irritability

• Unusual for this to occur at reasonable doses

• Some children sensitive to this effect for one of the stimulants, but not the other

• If other reasons cannot be found (such as new custody arrangements, loss of pet), this may be reason to change medication

• Not a fair trade off– child may be more attentive and focused but

feels unhappy or dysphoric

Page 30: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

“Rebound” phenomena

• Some researchers say this doesn’t exist

• Search for other causes of increased irritability toward end of school day or afternoon– Not eating, siblings home alone

• May be responsive to lowering dose over day, with short acting– 20 mg 7am, 20 mg. 11am, 10 mg. 3pm.

Page 31: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Need to change dose

• A dose may be effective for 1 to 2 years, and then need adjusting

• A dose is not necessarily increased every year

• Summers, holidays, weekends off?– Depends on target outcomes– May be management of poor weight gain

Page 32: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

How long to treat?

• Double blind controlled study not often done clinically– Cumbersome placebo production, hard to

mask the product– Expensive – not covered by insurance

• Adolescents often want to stop med• Patient learns to use med for targeted

outcomes and takes that skill into young adult years

Page 33: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

More than one medication for ADHD?

• Uncomplicated ADHD does not require more than one medication

• Most common rationale for more than one medication– Severe and disabling symptoms– Safety issues– Co-existing conditions

• Depression, tic disorder, obsessive compulsive disorder

Page 34: FDA Pediatric Advisory Committee June 30, 2005 Marsha D. Rappley, MD

Challenges of managing more than one medication

• Lack of guidance

• Difficulty discerning which needs to be adjusted

• Difficulty anticipating drug interactions

• Stimulants often among those used in combination pharmacotherapy